

HEW - Morbidity Study

R. J. REYNOLDS TOBACCO COMPANY

WINSTON-SALEM, NORTH CAROLINA

October 23, 1967.

H. H. RAMM  
VICE PRESIDENT AND GENERAL COUNSEL

David R. Hardy, Esq.,  
Shook, Hardy, Ottman, Mitchell & Bacon,  
915 Grand Avenue,  
Kansas City, Missouri. 64106.

Dear Dave:

I have your letter of October 20 relating to Dr. Sterling and the Morbidity Study of the HEW.

I am at a loss to understand Dr. Sterling's insistence that before presenting a statement or giving testimony in Congress concerning his analysis of the Morbidity Study he should have the opportunity to meet with Endicott's lung cancer committee and show them how the Morbidity Study is not entitled to any credence. I assume that by "lung cancer committee" is meant the Lung Cancer Task Force. I know of no procedures whereby anyone can appear before the Task Force and present views on any matter. Furthermore I do not recall that there is a word in the Morbidity Study concerning lung cancer.

Sincerely,

H. H. Ramm,  
Vice President and General Counsel.

HHR:W

CC: - The Honorable Earle C. Clements  
H. T. Austern, Esq.  
Frederick P. Haas, Esq.  
C. F. Hetsko, Esq.  
Paul Smith, Esq.  
Addison Yeaman, Esq.